이종욱 (가톨릭대학교)님 | 한빛사연구자 > 한빛사

가톨릭대학교

CV File

최종업데이트 2023.12.03.

- 이종욱(한양대학교병원, 현 가톨릭대학교)
Long-Term Efficacy and Safety of Danicopan as Add-On Therapy to Ravulizumab or Eculizumab in PNH With Significant EVH
- Blood, Dec 19 2024, blood.2024026299 | https://doi.org/10.1182/blood.2024026299
- 2024-12
- 의약학
- 한빛사논문
- 이종욱(가톨릭대학교)
Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial
- Lancet Haematol., Dec 2023, 10 (12) S2352-3026(23)00315-0 | https://doi.org/10.1016/S2352-3026(23)00315-0
- 2023-12
- 의약학
- 한빛사논문
Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial
- Lancet Haematol., Available online 29 August 2019 | https://doi.org/10.1016/S2352-3026(19)30153-X
- 2019-08
- 한빛사논문
- 이종욱(가톨릭대학교 의과대학, 서울성모병원)
Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study
- Blood, Prepublished online December 3, 2018 | doi: https://doi.org/10.1182/blood-2018-09-876136
- 2018-12
- 한빛사논문
- 이종욱(가톨릭대학교)
Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial
- Blood, 7 October 2010, Vol. 116, No. 14, pp. 2448-2454. Prepublished online June 21, 2010; DOI 10.1182/blood-2010-01-261289.
- 2010-06
- 한빛사논문

연구자 ID

저자논문

저자논문

저자논문

저자논문

CV 열람하기

연락처 보기